Vol. 6, Issue 1, Part A (2024)

Background: Despite of having guidelines for allergic rhinitis (AR) management, there are significant concerns in current scenario where the prevalence has been on the rise due to various factors. Hence, we aimed to analyse the prescription trends and patterns for AR treatment in clinical practice. 
Methodology: This was a questionnaire-based, cross sectional study in which the clinicians answered the online questionnaire containing questions pertaining to prevalence, symptoms, causes, clinical characteristics, management of AR and the usage of allergic medications in their clinical practice. The data were analysed using descriptive statistics. 
Results: About 41% of clinicians stated that 10-20 patients underwent treatment for AR per week. Both male and female patients were affected equally, and majority of the patients belonged to the age group 30-45 years. A peak in the patient inflow was seen during the months of December to February, with majority presenting symptoms such as breathing difficulty, constant sneezing, and rhinorrhoea. The most prescribed drug was bilastine + montelukast for 6 weeks by majority of the clinicians. they are reported that the preference give for this drug was due to its less sedative action, faster onset of action and the advantage it holds in the use in renal, hepatic, and geriatric patients. 
Conclusion: Bilastine was a widely used drug among majority of the clinicians for the plethora of benefits it has among all other allergic medications in the treatment of AR.